Amgen, navigating 'industry headwinds,' puts 300 commercial jobs on chopping block

As the biopharma industry flips the calendar on a new year, the threat of layoffs continues to loom for companies large and small.

Amgen is cutting around 300 jobs in the U.S.—mainly along commercial lines—a company spokesperson said in an email confirming “recently announced organizational changes.”